Which treatment is indicated for CME due to DM, RVO, OIS, or CNV?

Which treatment is indicated for CME due to DM, RVO, OIS, or CNV?

• A. Anti-VEGF
• B. Acetazolamide
• C. Ketorolac and Pred Acetate with taper
• D. Laser photocoagulation

Answer: (A)

The main idea is that CME in these conditions is driven by VEGF causing leakage from retinal vessels, so blocking VEGF directly tackles the root cause. Anti-VEGF agents injected into the eye inhibit VEGF activity, reduce vascular permeability, and shrink the macular edema, which improves or stabilizes vision across diabetic macular edema, macular edema from retinal vein occlusion, ocular ischemic syndrome with macular involvement, and CNV-related edema. This broad effectiveness across these etiologies explains why anti-VEGF is the best choice. Other options don’t address the primary driver as effectively. Acetazolamide can reduce fluid but doesn’t target VEGF-driven leakage and isn’t first-line for these conditions. Topical ketorolac with a corticosteroid taper may help in inflammatory or postoperative CME but is not a reliable mainstay for chronic CME due to diabetes, RVO, OIS, or CNV. Laser photocoagulation can reduce edema in some BRVO cases, but it’s generally less effective than anti-VEGF therapy for DME and RVO-related CME and doesn’t address CNV, making it a less comprehensive option.

The main idea is that CME in these conditions is driven by VEGF causing leakage from retinal vessels, so blocking VEGF directly tackles the root cause. Anti-VEGF agents injected into the eye inhibit VEGF activity, reduce vascular permeability, and shrink the macular edema, which improves or stabilizes vision across diabetic macular edema, macular edema from retinal vein occlusion, ocular ischemic syndrome with macular involvement, and CNV-related edema. This broad effectiveness across these etiologies explains why anti-VEGF is the best choice.

Other options don’t address the primary driver as effectively. Acetazolamide can reduce fluid but doesn’t target VEGF-driven leakage and isn’t first-line for these conditions. Topical ketorolac with a corticosteroid taper may help in inflammatory or postoperative CME but is not a reliable mainstay for chronic CME due to diabetes, RVO, OIS, or CNV. Laser photocoagulation can reduce edema in some BRVO cases, but it’s generally less effective than anti-VEGF therapy for DME and RVO-related CME and doesn’t address CNV, making it a less comprehensive option.